ATYR Stock Summary and Trading Ideas (Atyr Pharma | NASDAQ:ATYR)

aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).

Atyr Pharma trades on the NASDAQ stock market under the symbol ATYR.

As of March 26, 2026, ATYR stock price climbed to $0.81 with 114,103 million shares trading.

ATYR has a beta of 1.06, meaning it tends to be more sensitive to market movements. ATYR has a correlation of 0.01 to the broad based SPY ETF.

ATYR has a market cap of $79.37 million. This is considered a Micro Cap stock.

Last quarter Atyr Pharma reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-20,000 and exceeded earnings estimates by $.04.

The top ETF exchange traded funds that ATYR belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.

ATYR has underperformed the market in the last year with a price return of -76.8% while the SPY ETF gained +14.8%. However, in the short term, ATYR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.7% vs -5.1% return in SPY. But in the last 2 weeks, ATYR shares have been beat by the market, returning -12.1% compared to an SPY return of -3.1%.

ATYR support price is $.76 and resistance is $.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATYR shares will trade within this expected range on the day.